Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Mind Cure Health will be focus its psychedelics R&D on psilocybin, ketamine and ibogaine. The Company will pursue both pain-based and mental health applications.
ATAI Life Science's IPO in 2021 is expected to be another big industry catalyst. But one company that might NOT benefit is Compass Pathways.
Nearly $400 million dollars has recently flooded into the coffers of psychedelic drug companies. That's enough capital to power a lot of growth.
Oregon’s effort to create a new psilocybin-assisted therapy system has attracted attention from across the country.